Research Analysts Issue Forecasts for AMAG Pharmaceuticals, Inc.’s FY2020 Earnings (NASDAQ:AMAG)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Equities researchers at Svb Leerink raised their FY2020 EPS estimates for AMAG Pharmaceuticals in a report released on Monday, October 7th. Svb Leerink analyst A. Fadia now anticipates that the specialty pharmaceutical company will post earnings of ($2.52) per share for the year, up from their prior estimate of ($3.27). Svb Leerink also issued estimates for AMAG Pharmaceuticals’ FY2021 earnings at ($0.44) EPS, FY2022 earnings at $0.08 EPS and FY2023 earnings at ($0.29) EPS.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.62). AMAG Pharmaceuticals had a negative return on equity of 31.31% and a negative net margin of 64.33%. The business had revenue of $78.00 million during the quarter, compared to the consensus estimate of $90.72 million. During the same quarter in the prior year, the firm posted ($0.75) EPS. The company’s revenue for the quarter was down 46.6% on a year-over-year basis.

Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $9.25 price target on the stock in a research report on Thursday, June 20th. Piper Jaffray Companies restated a “neutral” rating and issued a $9.00 price target on shares of AMAG Pharmaceuticals in a research report on Wednesday, August 7th. Cowen restated a “hold” rating and issued a $13.00 price target on shares of AMAG Pharmaceuticals in a research report on Monday, June 24th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, August 8th. Finally, ValuEngine upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $14.69.

Shares of AMAG opened at $11.05 on Thursday. The company’s fifty day moving average is $11.58 and its 200 day moving average is $10.74. AMAG Pharmaceuticals has a fifty-two week low of $6.81 and a fifty-two week high of $23.77. The stock has a market capitalization of $385.22 million, a PE ratio of -2.85 and a beta of 0.39. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.50 and a current ratio of 1.60.

A number of hedge funds have recently bought and sold shares of AMAG. Great West Life Assurance Co. Can boosted its stake in shares of AMAG Pharmaceuticals by 7.3% during the first quarter. Great West Life Assurance Co. Can now owns 48,184 shares of the specialty pharmaceutical company’s stock valued at $620,000 after purchasing an additional 3,260 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in shares of AMAG Pharmaceuticals by 22.2% during the first quarter. DekaBank Deutsche Girozentrale now owns 18,150 shares of the specialty pharmaceutical company’s stock valued at $445,000 after purchasing an additional 3,300 shares during the period. NumerixS Investment Technologies Inc boosted its stake in shares of AMAG Pharmaceuticals by 17.8% during the first quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,083 shares during the period. ClariVest Asset Management LLC boosted its stake in shares of AMAG Pharmaceuticals by 56.5% during the first quarter. ClariVest Asset Management LLC now owns 154,776 shares of the specialty pharmaceutical company’s stock valued at $1,993,000 after purchasing an additional 55,892 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of AMAG Pharmaceuticals during the second quarter valued at $324,000.

In other news, major shareholder Camber Capital Management Lp acquired 385,000 shares of the business’s stock in a transaction on Friday, August 9th. The shares were acquired at an average price of $7.87 per share, for a total transaction of $3,029,950.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Armistice Capital, Llc acquired 260,000 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were purchased at an average price of $7.32 per share, for a total transaction of $1,903,200.00. The disclosure for this purchase can be found here. Insiders own 4.90% of the company’s stock.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Further Reading: Technical Indicators – What is a Golden Cross?

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit